Costimulation Blockade in Autoimmunity and Transplantation: The CD28 Pathway

Area of Science:

• Immunology
• Molecular Biology
• Cell Signaling

Background:

• T cell activation requires primary signals and costimulatory signals for full response.
• Absence of costimulatory signals can lead to T cell anergy.
• The CD28/CTLA-4 and CD80/CD86 pathway is a key costimulatory pathway.

Purpose of the Study:

• To review the role of CD28 and CTLA-4 in T cell activation.
• To highlight the success of CTLA-4-Ig fusion proteins as therapeutics.
• To discuss future therapeutic strategies involving selective blockade of CD28.

Main Methods:

• Review of existing literature on T cell costimulation.
• Analysis of the mechanism of action for CTLA-4-Ig.
• Discussion of potential future therapeutic targets.

Main Results:

• CTLA-4-Ig fusion proteins (abatacept, belatacept) are effective treatments for rheumatoid arthritis and transplant rejection.
• CD28 and CTLA-4 play critical, distinct roles in T cell costimulation and coinhibition.
• Selective CD28 blockade presents a potential future therapeutic avenue.

Conclusions:

• Targeting costimulatory pathways like CD28/CTLA-4 has yielded successful immunotherapies.
• CTLA-4-Ig fusion proteins represent a significant advancement in treating immune-mediated conditions.
• Future research may focus on selective modulation of CD28 and CTLA-4 signaling for tailored therapeutic outcomes.